<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033145</url>
  </required_header>
  <id_info>
    <org_study_id>FNC IGZ-2</org_study_id>
    <nct_id>NCT05033145</nct_id>
  </id_info>
  <brief_title>Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)</brief_title>
  <official_title>Evaluation of the Safety and Clinical Efficacy of AZVUDINE: Randomized, Double-blind, Placebo-controlled Study in Mild Stage Patients Infected With the SARS-CoV-2 Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HRH Pharmaceuticals Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Unit / High Complexity Center (CRU/HCC) / Galzu Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HRH Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, single-center, randomized, double-blind, parallel, placebo-controlled clinical&#xD;
      study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      AZVUDINE has a therapeutic potential and safety profile for the treatment of patients&#xD;
      infected with SARS-CoV-2.&#xD;
&#xD;
      Goals:&#xD;
&#xD;
      Main goal:&#xD;
&#xD;
      A. Consolidate scientific and technological cooperation between researchers from Brazil,&#xD;
      China, and Russia (member countries of the BRICS), aiming to achieve world-class technical&#xD;
      and scientific results on the theme of COVID-19.&#xD;
&#xD;
      B. To evaluate the effectiveness and safety of AZVUDINE tablets for the treatment of&#xD;
      COVID-19, during the initial stage and mild symptoms, compared to conventional treatment&#xD;
      [period: 14 days].&#xD;
&#xD;
      Specific objective:&#xD;
&#xD;
      To evaluate the clinical evolution of participants infected by SARS-CoV-2 treated with&#xD;
      AZVUDINE (FNC) compared to placebo in the mild stage.&#xD;
&#xD;
      Statistical planning:&#xD;
&#xD;
      Statistical description: all statistical tests are performed by bilateral testing. A&#xD;
      significance level of 5% will be adopted.&#xD;
&#xD;
      Baseline analysis: including subject distribution, data demographics, and baseline analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, parallel, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalized patients proportion during the study</measure>
    <time_frame>Day 15, Day 21 and Day 28 (approximately 14-30 days).</time_frame>
    <description>Proportion of patients hospitalized during the study until Day 28, according to World Health Organization Ordinal Clinical Progression Scale (WHO, Jun/2020; scale 0 [asymptomatic] to 10 [death]), with score 4 to 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with clinical evolution of cure during the study</measure>
    <time_frame>Day 1 to Day 15, Day 21 and Day 28 (approximately 14-30 days).</time_frame>
    <description>The clinical outcome of cure is defined in this protocol as the absence of viral RNA in the collected samples and clinical conditions for outpatient discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of participant clinical status</measure>
    <time_frame>Day 1 to Day 15 (approximately 14 days).</time_frame>
    <description>Improvement of clinical status in at least one category compared to screening on the Ordinal Clinical Improvement Scale (WHO, Jun/2020)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity and duration of clinical symptoms</measure>
    <time_frame>Day 15, Day 21 and Day 28 (approximately 14-30 days).</time_frame>
    <description>Severity and duration of fever, cough, fatigue or tiredness, high breathing, myalgia, nasal congestion or runny nose, sore throat, headache, chills, nausea, vomiting, anosmia, ageusia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of renal function biochemical markers (serum creatinine and calculated glomerular filtration rate)</measure>
    <time_frame>Day 1 to Day 15, Day 21, Day 28, and Day 60.</time_frame>
    <description>Rate of change in biochemical markers of renal function in relation to the physiological reference intervals between the AZVUDINE and PLACEBO groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of liver function biochemical markers (AST/TGO, ALT/TGP, ALP, GGT, BIL total, and direct BIL)</measure>
    <time_frame>Day 1 to Day 15, Day 21, Day 28, and Day 60.</time_frame>
    <description>Rate of change in biochemical markers of hepatic function in relation to the physiological reference intervals between the AZVUDINA and PLACEBO groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of time to negative conversion of SARS-CoV-2 viral load by RT-PCR</measure>
    <time_frame>Day 1 to Day 15, Day 21 and Day 28 (approximately 14-30 days).</time_frame>
    <description>Time (days) to negative conversion of the SARS-CoV-2 viral load between AZVUDINE (FNC) and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the number of cycles for the detection of SARS-CoV-2 viral load by RT-PCR and application of the standard curve for calculating viral load.</measure>
    <time_frame>Day 1 to Day 15 (approximately 14 days).</time_frame>
    <description>SARS-CoV-2 viral load determination by standard-curve method of quantification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the relationship between the calculated viral load and the clinical evolution of the participants in experimental (FNC) and PLACEBO groups.</measure>
    <time_frame>Day 1 to Day 15, Day 21 and Day 28 (approximately 14-30 days).</time_frame>
    <description>Rating the relationship between viral load calculated and clinical outcomes of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of drug interaction events.</measure>
    <time_frame>Day 1 to Day 15, Day 21 and Day 28 (approximately 14-30 days).</time_frame>
    <description>Frequency of drug interaction events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality assessment.</measure>
    <time_frame>Day 1 to Day 60 (approximately 14-60 days).</time_frame>
    <description>Mortality rate during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events frequency.</measure>
    <time_frame>Day 1 to Day 28 (approximately 14-30 days).</time_frame>
    <description>Frequency of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events intensity.</measure>
    <time_frame>Day 1 to Day 28 (approximately 14-30 days).</time_frame>
    <description>Intensity of adverse events (1= Mild; 2= Moderate; 3= Severe; 4= Critical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of unexpected adverse events frequency.</measure>
    <time_frame>Day 1 to Day 28 (approximately 14-30 days).</time_frame>
    <description>Frequency of unexpected adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of unexpected adverse events intensity.</measure>
    <time_frame>Day 1 to Day 28 (approximately 14-30 days).</time_frame>
    <description>Intensity of unexpected adverse events (1= Mild; 2= Moderate; 3= Severe; 4= Critical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of serious adverse events frequency.</measure>
    <time_frame>Day 1 to Day 28 (approximately 14-30 days).</time_frame>
    <description>Frequency of serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of serious adverse events intensity.</measure>
    <time_frame>Day 1 to Day 28 (approximately 14-30 days).</time_frame>
    <description>Intensity of serious adverse events (1= Mild; 2= Moderate; 3= Severe; 4= Critical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the tolerability of azvudine in the 5 mg regimen orally QD up to 14 days.</measure>
    <time_frame>Day 1 to Day 15 (approximately 14 days).</time_frame>
    <description>Treatment dropout rate due to AZVUDINE/Placebo intolerance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adherence of azvudine in the 5 mg regimen orally QD up to 14 days.</measure>
    <time_frame>Day 1 to Day 15 (approximately 14 days).</time_frame>
    <description>Medication possession rate, to measure the proportion of administered dose episodes observed in relation to the expected number of doses, until treatment interruption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of use of azvudine in the 5 mg regimen orally QD up to 14 days.</measure>
    <time_frame>Day 1 to Day 15 (approximately 14 days).</time_frame>
    <description>Total time (days) of use of AZVUDINE / Placebo intolerance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>AZVUDINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental:&#xD;
AZVUDINE 1mg tablet&#xD;
Interventions:&#xD;
AZVUDINE 1mg tablet, 5 tablets QD + standard treatment, for up to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZVUDINE placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control:&#xD;
AZVUDINE placebo&#xD;
Intervention:&#xD;
AZVUDINE placebo tablet, 5 tablets QD + standard treatment, for up to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZVUDINE</intervention_name>
    <description>AZVUDINE 5 tablets QD + standard treatment, for up to 14 days</description>
    <arm_group_label>AZVUDINE</arm_group_label>
    <other_name>AZVUDINE 1 mg tablets</other_name>
    <other_name>FNC</other_name>
    <other_name>4-amino-1-((2R,3S,4R,5R)-5-azido-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2(1H)-one</other_name>
    <other_name>1-(4-Azido-2-deoxy-2-fluoro-beta-D- arabino Ribo-furanosyl) cytosine, FNC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZVUDINE placebo</intervention_name>
    <description>5 tablets QD + standard treatment, for up to 14 days</description>
    <arm_group_label>AZVUDINE placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years, regardless of gender;&#xD;
&#xD;
          2. The result of the RT-PCR test by fluorescence of respiratory or blood samples must be&#xD;
             positive for COVID-19, or the viral gene sequencing of respiratory tract samples must&#xD;
             be highly homologous with COVID-19; Individuals with COVID-19 must meet the diagnostic&#xD;
             criteria of the &quot;latest version of the clinical guidelines for COVID-19&quot; issued by the&#xD;
             World Health Organization (WHO) on June 4th, 2020;&#xD;
&#xD;
          3. Symptomatic patients who meet the WHO case definition for COVID-19 with no evidence of&#xD;
             bacterial pneumonia or hypoxia (Sat O2 &lt;95%).&#xD;
&#xD;
          4. Voluntary participation and signing of the Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Be aware or suspected of being allergic to any of the components of AZVUDINE tablets&#xD;
             (inactive ingredients: microcrystalline cellulose, hydrated lactose,&#xD;
             polyvinylpyrrolidone K30, croscarmellose sodium, magnesium stearate);&#xD;
&#xD;
          2. Individual with shortness of breath and Sat O2 &lt; 95%; or any other symptom that&#xD;
             requires treatment through hospitalization;&#xD;
&#xD;
          3. Patients with liver disease (total bilirubin ≥2mg/dL, ALT/TGP, and AST/TGO ≥5 times&#xD;
             the normal limit);&#xD;
&#xD;
          4. Patients with a history of known liver disease (Chirrhosis, with ChildPugh&#xD;
             classification B and C);&#xD;
&#xD;
          5. Patients with a history of renal failure (Glomerular Filtration Rate&#xD;
             &lt;/=60mL/min/1.73m²);&#xD;
&#xD;
          6. Patients with a history of congestive heart failure (grade 3/4 NYHA), untreated&#xD;
             symptomatic arrhythmias, or myocardial infarction for 6 months;&#xD;
&#xD;
          7. Individuals with malabsorption syndrome, or other conditions that affect&#xD;
             gastrointestinal absorption, and circumstances in which patients require intravenous&#xD;
             nutrition, or cannot take medications by mouth or nasogastric;&#xD;
&#xD;
          8. Total neutrophil count &lt;750 cells/L;&#xD;
&#xD;
          9. Women who are pregnant or lactating, or of childbearing potential during the study&#xD;
             period and within 6 months after termination of administration;&#xD;
&#xD;
         10. Individuals who have participated in another clinical trial and used an experimental&#xD;
             drug in the past 12 weeks;&#xD;
&#xD;
         11. Patient actively being treated for HIV, Hepatitis C, or Hepatitis B;&#xD;
&#xD;
         12. Patients being treated with other antivirals (e.g., lopinavir/ritonavir, remdesivir,&#xD;
             umifenovir/arbidol, favipiravir, interferon-α) or immunosuppressive drugs for other&#xD;
             medical conditions;&#xD;
&#xD;
         13. Patients being treated with monoclonal antibodies (e.g., tocilizumab and&#xD;
             sarilumab/kevzara);&#xD;
&#xD;
         14. Any clinically significant medical condition or medical history that, in the&#xD;
             investigator's opinion, may discourage study participation, such as corrected QT&#xD;
             interval &gt;480 on the electrocardiogram, among other conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George J Mota, Pharm BSc</last_name>
    <role>Study Chair</role>
    <affiliation>Galzu Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renato S Martins, MSc, PhD</last_name>
    <phone>+55 22 99998-5248</phone>
    <email>rjrenato@icloud.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paula G Cabral, MSc, PhD</last_name>
    <phone>+55 22 98126-6602</phone>
    <email>pgacabral99@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Unit / High Complexity Center (CRU/HCC) / Galzu Institute</name>
      <address>
        <city>Campos Dos Goytacazes</city>
        <state>Rio De Janeiro</state>
        <zip>28110-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Paula G Cabral, MSc, PhD</last_name>
      <phone>+55 22 98126-6602</phone>
      <email>pgacabral99@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Renato S Martins, MSc, PhD</last_name>
      <phone>+55 22 99998-5248</phone>
      <email>rjrenato@icloud.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Augusto A Tavares, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Moacyr Gomes de Azevedo</name>
      <address>
        <city>Cambuci</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <investigator>
      <last_name>Tiago Carvalho Velasco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Casa de Misericórdia de Campos</name>
      <address>
        <city>Campos Dos Goytacazes</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <investigator>
      <last_name>Cleber Glória Silva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unidade de Pesquisa Clínica / Centro de Alta Complexidade</name>
      <address>
        <city>Campos dos Goytacazes</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <investigator>
      <last_name>Carlos Augusto de Araújo Tavares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unidade Pré Hospitalar São José</name>
      <address>
        <city>Campos Dos Goytacazes</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <investigator>
      <last_name>Bruno Hanry Fonseca Ribeiro de Lima Viana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>João Manoel Paravidino de Souza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Itaocara</name>
      <address>
        <city>Itaocara</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <investigator>
      <last_name>Elenio Melo de Almeida, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Armando Vidal</name>
      <address>
        <city>São Fidelis</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <investigator>
      <last_name>Antonio Rodrigo Serra Santarém, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZVUDINE</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>FNC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

